

João«lle Choueiry

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3978193/publications.pdf>

Version: 2024-02-01

26
papers

403
citations

686830

13
h-index

752256

20
g-index

26
all docs

26
docs citations

26
times ranked

495
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Ketamine on Resting-State EEG Activity and Their Relationship to Perceptual/Dissociative Symptoms in Healthy Humans. <i>Frontiers in Pharmacology</i> , 2016, 7, 348.	1.6	79
2	Neurocognitive effects of acute choline supplementation in low, medium and high performer healthy volunteers. <i>Pharmacology Biochemistry and Behavior</i> , 2015, 131, 119-129.	1.3	31
3	Baseline dependency of nicotine's sensory gating actions: similarities and differences in low, medium and high P50 suppressors. <i>Journal of Psychopharmacology</i> , 2013, 27, 790-800.	2.0	30
4	Baseline-dependent modulating effects of nicotine on voluntary and involuntary attention measured with brain event-related P3 potentials. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 122, 107-117.	1.3	28
5	Modulation of auditory deviance detection by acute nicotine is baseline and deviant dependent in healthy nonsmokers: a mismatch negativity study. <i>Human Psychopharmacology</i> , 2014, 29, 446-458.	0.7	26
6	The moderating role of the dopamine transporter 1 gene on P50 sensory gating and its modulation by nicotine. <i>Neuroscience</i> , 2011, 180, 148-156.	1.1	25
7	CDP-choline: Effects of the procholine supplement on sensory gating and executive function in healthy volunteers stratified for low, medium and high P50 suppression. <i>Journal of Psychopharmacology</i> , 2014, 28, 1095-1108.	2.0	24
8	Effects of COMT genotype on sensory gating and its modulation by nicotine: Differences in low and high P50 suppressors. <i>Neuroscience</i> , 2013, 241, 147-156.	1.1	23
9	An acute dose, randomized trial of the effects of CDP-Choline on Mismatch Negativity (MMN) in healthy volunteers stratified by deviance detection level. <i>Neuropsychiatric Electrophysiology</i> , 2015, 1, .	4.1	19
10	Combining CDP-choline and galantamine, an optimized ± 7 nicotinic strategy, to ameliorate sensory gating to speech stimuli in schizophrenia. <i>International Journal of Psychophysiology</i> , 2019, 145, 70-82.	0.5	17
11	Combining CDP-choline and galantamine: Effects of a selective ± 7 nicotinic acetylcholine receptor agonist strategy on P50 sensory gating of speech sounds in healthy volunteers. <i>Journal of Psychopharmacology</i> , 2019, 33, 688-699.	2.0	15
12	NMDA Receptor Antagonist Effects on Speech-Related Mismatch Negativity and Its Underlying Oscillatory and Source Activity in Healthy Humans. <i>Frontiers in Pharmacology</i> , 2019, 10, 455.	1.6	14
13	Effects of acute CDP-choline treatment on resting state brain oscillations in healthy volunteers. <i>Neuroscience Letters</i> , 2015, 591, 121-125.	1.0	13
14	It's in the timing: reduced temporal precision in neural activity of schizophrenia. <i>Cerebral Cortex</i> , 2022, 32, 3441-3456.	1.6	13
15	COMT polymorphism modulates the resting-state EEG alpha oscillatory response to acute nicotine in male non-smokers. <i>Genes, Brain and Behavior</i> , 2015, 14, 466-476.	1.1	7
16	Mismatch negativity in tobacco-naïve cannabis users and its alteration with acute nicotine administration. <i>Pharmacology Biochemistry and Behavior</i> , 2015, 136, 73-81.	1.3	7
17	Cholinergic modulation of auditory P3 event-related potentials as indexed by CHRNA4 and CHRNA7 genotype variation in healthy volunteers. <i>Neuroscience Letters</i> , 2016, 623, 36-41.	1.0	7
18	CDP-choline and galantamine, a personalized ± 7 nicotinic acetylcholine receptor targeted treatment for the modulation of speech MMN indexed deviance detection in healthy volunteers: a pilot study. <i>Psychopharmacology</i> , 2020, 237, 3665-3687.	1.5	7

#	ARTICLE	IF	CITATIONS
19	Acute separate and combined effects of cannabinoid and nicotinic receptor agonists on MMN-indexed auditory deviance detection in healthy humans. <i>Pharmacology Biochemistry and Behavior</i> , 2019, 184, 172739.	1.3	6
20	Resting-state functional EEG connectivity in salience and default mode networks and their relationship to dissociative symptoms during NMDA receptor antagonism. <i>Pharmacology Biochemistry and Behavior</i> , 2021, 201, 173092.	1.3	5
21	N-methyl-D-aspartate receptor antagonism modulates P300 event-related potentials and associated activity in salience and central executive networks. <i>Pharmacology Biochemistry and Behavior</i> , 2021, 211, 173287.	1.3	4
22	The acute dose and baseline amplitude-dependent effects of CDP-choline on deviance detection (MMN) in chronic schizophrenia: A pilot study.. <i>Experimental and Clinical Psychopharmacology</i> , 2022, 30, 235-248.	1.3	2
23	Sensory gating in tobacco-naïve cannabis users is unaffected by acute nicotine administration. <i>Psychopharmacology</i> , 2022, 239, 1279-1288.	1.5	1
24	Effect of GAD1 genotype status on auditory attention and acute nicotine administration in healthy volunteers. <i>Human Psychopharmacology</i> , 2019, 34, e2684.	0.7	0
25	Ketamine Effects on P50 Sensory Gating of Speech Sounds and Source Activity in Healthy Volunteers. <i>Biological Psychiatry</i> , 2021, 89, S255-S256.	0.7	0
26	Targeted ± 7 Nicotinic Acetylcholine Receptor Treatment for the Modulation of Speech MMN in Schizophrenia: An Optimized CDP-Choline and Galantamine Combination Approach Personalized to Baseline-Deviance Detection Levels. <i>Biological Psychiatry</i> , 2021, 89, S340-S341.	0.7	0